Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
On September 10, 2021, Akari Therapeutics (Nasdaq: AKTX) announced that Dr. Miles Nunn and Dr. Sanjeev Khindri will present a poster on the Phase III study design of nomacopan for treating moderate to severe bullous pemphigoid (BP) at the 2021 IPPF Scientific Symposium. The trial aims to evaluate nomacopan's safety and its capacity to control BP symptoms while reducing reliance on systemic steroids. The presentation is scheduled for September 20, 2021. Akari focuses on innovative therapeutics for orphan autoimmune diseases and has identified significant potential for nomacopan as a targeted therapy.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced that CEO Clive Richardson will present at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13-15, 2021. The presentation will highlight Akari's focus on innovative therapies for orphan autoimmune and inflammatory diseases, particularly its lead drug candidate, Nomacopan, a dual C5 complement and leukotriene B4 inhibitor. Investors can access the webcast on-demand starting September 13, 2021, at 7:00 a.m. ET on the Akari website.
Akari Therapeutics (Nasdaq: AKTX) has announced a private placement of equity securities, aiming to raise approximately $12 million. This funding will be achieved through the issuance of unregistered American Depository Shares (ADSs) at $1.55 each, representing 100 ordinary shares. The offering's closing is expected by the week of July 12, 2021, pending standard closing conditions. Paulson Investment Company is acting as the exclusive placement agent. Akari focuses on innovative therapeutics for orphan autoimmune diseases, with its lead candidate, Nomacopan, in clinical evaluation for multiple conditions.
Akari Therapeutics has opened an Investigational New Drug (IND) application with the FDA for a Phase III study of nomacopan targeting bullous pemphigoid and pediatric HSCT-TMA. The company reported a net loss of approximately $5.8 million for Q1 2021, higher than last year's $3.7 million. Cash reserves decreased to $6.7 million. The ongoing development of nomacopan also includes potential treatments for dry age-related macular degeneration and various lung diseases. Akari’s operational team is expanding as part of its strategy to advance its clinical programs.
Akari Therapeutics (Nasdaq: AKTX) has initiated a multicenter Phase III study for nomacopan, targeting moderate and severe bullous pemphigoid (BP). This treatment aims to replace long-term steroid usage, which poses significant health risks to elderly patients. The FDA has granted Fast Track and orphan drug designations for nomacopan, facilitating quicker development and review processes. Success in treating BP could extend nomacopan's application to other severe skin conditions. BP affects around 120,000 patients in the U.S. and EU, predominantly in moderate and severe stages.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced the presentation of a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience from April 23-25, 2021. The poster, titled “Disease Remission During a Short-term Treatment Phase II Study of Nomacopan in Mild-to-moderate Bullous Pemphigoid,” highlights results from a Phase II study focusing on disease control metrics. The upcoming Phase III trial for nomacopan will open for recruitment mid-2021, following FDA and EMA clearance, as Akari continues its focus on treating orphan diseases through novel therapeutics.
Akari Therapeutics has opened Investigational New Drug Applications with the FDA for Phase III studies of nomacopan, targeting bullous pemphigoid and pediatric HSCT-TMA. New data suggests nomacopan's potential in treating dry age-related macular degeneration and COVID-19 pneumonia. Positive long-term data shows that nomacopan is well-tolerated in paroxysmal nocturnal hemoglobinuria patients, reducing transfusion dependence by 79%. Financial results for 2020 show cash increased to $14.1 million, though a net loss of $17.1 million was reported.
Akari Therapeutics has opened an investigational new drug application (IND) with the FDA for nomacopan, targeting moderate to severe bullous pemphigoid (BP). Clinical recruitment is set to commence by mid-2021, pending COVID-19 restrictions. Nomacopan has received orphan drug designation from both the FDA and EMA. The Phase III trial aims to validate nomacopan’s unique therapeutic advantages, based on successful Phase II studies, with a focus on patient remission.
Akari Therapeutics announces a cooperative research and development agreement with the U.S. Army Institute of Surgical Research (USAISR) to study nomacopan for trauma treatment. This investigational drug targets inflammation in trauma cases, showing promise in conditions like traumatic brain injury and myocardial infarction. The study aims to evaluate nomacopan's efficacy in preclinical trauma models. With trauma being a leading cause of death under 45 years, Akari aims to address the lack of approved therapies, potentially benefiting both military and civilian patients.
Akari Therapeutics (Nasdaq: AKTX) announced new findings published in CELLS revealing the role of LTB4 in promoting VEGF-related retinal inflammation, contributing to wet AMD. In preclinical models, PAS-nomacopan, a long-acting version of their drug, significantly reduced neo-vascularization equivalent to the FDA-approved Eyelea®. The study demonstrated over 50% reduction in VEGF levels in uveitis models, highlighting PAS-nomacopan's dual mechanism of action that inhibits both LTB4 and complement C5, potentially offering new treatment avenues for eye diseases.